Clinical Trials Logo

Qt Interval, Variation in clinical trials

View clinical trials related to Qt Interval, Variation in.

Filter by:

NCT ID: NCT02063620 Completed - Clinical trials for Qt Interval, Variation in

The Effect of Anesthetic Agents Management on ECG Changes of Patients Who Were Operated Under RIVA

Start date: October 2013
Phase: N/A
Study type: Interventional

IVRA can be performed with many local anesthetics and adjuvant agents. Investigators planned to compare cardiac effects and ECG changes by IVRA with lidocaine and lidocaine plus ketamine.

NCT ID: NCT01365806 Completed - Clinical trials for Qt Interval, Variation in

Home Electrocardiogram (ECG) Monitoring After Heart Transplantation

NEW HEART
Start date: August 2011
Phase: N/A
Study type: Observational

The long-term goal of this research is to apply novel technology for detection of donor organ (allograft) rejection to improve patient outcomes following heart transplantation. The specific goal of this study is to determine whether daily monitoring of the transplant recipient's electrocardiogram (ECG) using a simple home device with transmission to an ECG Core Laboratory would provide an early biomarker for acute rejection. Despite routine immunosuppressant drug therapy, acute rejection is common, especially within the first 6 months following transplant surgery. To detect rejection, frequent endomyocardial biopsies of heart tissue are performed. An endomyocardial biopsy is a costly and invasive procedure performed in a hospital cardiac catheterization laboratory that has associated risks. Recent evidence suggests that acute allograft rejection causes delays in ventricular repolarization resulting in a longer QT interval on the ECG. The specific aims of the study are to: 1) determine whether an increase in the QT interval during the first 6 months following heart transplant is a sensitive and specific biomarker for acute rejection; and 2) determine the timing of QT interval increases relative to biopsy-diagnosed stages of mild/moderate/severe rejection. The potential benefit of finding a simple ECG biomarker of allograph rejection that could be measured at home is that it might yield earlier detection of rejection, allow more timely therapy and reduce mortality from acute allograft rejection.